General Counsel & Secretary Of Outset Medical Sold 58% Of Their Shares

Investors may wish to note that the General Counsel & Secretary of Outset Medical, Inc., John Brottem, recently netted US$51k from selling stock, receiving an average price of US$4.78. While that isn't a lot of money, it was a substantial 58% of their holding, so certainly isn't a good sign.

Check out our latest analysis for Outset Medical

Outset Medical Insider Transactions Over The Last Year

The Senior Vice President of Operations and R&D, Marc Nash, made the biggest insider sale in the last 12 months. That single transaction was for US$291k worth of shares at a price of US$429 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$3.64. So it is hard to draw any strong conclusion from it.

Insiders in Outset Medical didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Does Outset Medical Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own US$3.6m worth of Outset Medical stock, about 1.9% of the company. We prefer to see high levels of insider ownership.

So What Does This Data Suggest About Outset Medical Insiders?

Insiders sold Outset Medical shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. We'd certainly practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Be aware that Outset Medical is showing 4 warning signs in our investment analysis, and 1 of those is potentially serious...

But note: Outset Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com